X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PFIZER - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PFIZER SUN PHARMA/
PFIZER
 
P/E (TTM) x 35.1 33.3 105.5% View Chart
P/BV x 3.7 4.9 76.5% View Chart
Dividend Yield % 0.3 0.7 48.4%  

Financials

 SUN PHARMA   PFIZER
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
PFIZER
Mar-18
SUN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7012,365 29.6%   
Low Rs4331,625 26.7%   
Sales per share (Unadj.) Rs110.4430.3 25.7%  
Earnings per share (Unadj.) Rs11.078.7 13.9%  
Cash flow per share (Unadj.) Rs17.293.2 18.5%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.41.0 35.2%  
Book value per share (Unadj.) Rs158.8586.5 27.1%  
Shares outstanding (eoy) m2,399.2645.75 5,244.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.6 110.7%   
Avg P/E ratio x51.625.3 203.7%  
P/CF ratio (eoy) x32.921.4 153.7%  
Price / Book Value ratio x3.63.4 104.9%  
Dividend payout %18.225.4 71.7%   
Avg Mkt Cap Rs m1,360,02191,271 1,490.1%   
No. of employees `00017.82.6 676.4%   
Total wages/salary Rs m53,6713,143 1,707.7%   
Avg. sales/employee Rs Th14,890.97,484.8 198.9%   
Avg. wages/employee Rs Th3,017.11,195.0 252.5%   
Avg. net profit/employee Rs Th1,480.61,369.1 108.1%   
INCOME DATA
Net Sales Rs m264,89519,685 1,345.7%  
Other income Rs m8,3881,143 733.9%   
Total revenues Rs m273,28220,828 1,312.1%   
Gross profit Rs m56,0815,003 1,121.0%  
Depreciation Rs m14,998663 2,263.9%   
Interest Rs m5,1764 123,231.0%   
Profit before tax Rs m44,2955,479 808.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,878 450.0%   
Profit after tax Rs m26,3383,601 731.5%  
Gross profit margin %21.225.4 83.3%  
Effective tax rate %19.134.3 55.7%   
Net profit margin %9.918.3 54.4%  
BALANCE SHEET DATA
Current assets Rs m316,35924,167 1,309.0%   
Current liabilities Rs m198,6439,544 2,081.3%   
Net working cap to sales %44.474.3 59.8%  
Current ratio x1.62.5 62.9%  
Inventory Days Days9555 172.1%  
Debtors Days Days10829 375.2%  
Net fixed assets Rs m213,1789,514 2,240.8%   
Share capital Rs m2,399458 524.4%   
"Free" reserves Rs m378,60626,375 1,435.5%   
Net worth Rs m381,00626,832 1,420.0%   
Long term debt Rs m17,72125 70,883.6%   
Total assets Rs m643,02836,900 1,742.6%  
Interest coverage x9.61,305.5 0.7%   
Debt to equity ratio x00 4,991.9%  
Sales to assets ratio x0.40.5 77.2%   
Return on assets %4.99.8 50.2%  
Return on equity %6.913.4 51.5%  
Return on capital %10.020.4 49.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81622 182,216.1%   
Fx outflow Rs m30,1431,489 2,024.8%   
Net fx Rs m10,673-1,466 -727.9%   
CASH FLOW
From Operations Rs m39,0723,318 1,177.6%  
From Investments Rs m-33,708-2,383 1,414.5%  
From Financial Activity Rs m-15,393-1,104 1,394.9%  
Net Cashflow Rs m-7,359-169 4,367.4%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.1 7.5 68.4%  
FIIs % 23.0 4.9 469.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.7 35.0%  
Shareholders   133,026 85,207 156.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Oct 17, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS